FDA okays fruit-flavored vapes

Vapes are back in the middle of the public-health fight — but this time the argument is narrower than “flavors good” or “flavors bad.” On May 5, 2026, the FDA authorized four pods from Los Angeles-based Glas, including two fruit flavors sold as Gold and Sapphire. That makes them the first non-tobacco, non-menthol e-cigarettes the agency has allowed onto the legal U.S. market. The whole case turns on one idea: maybe a flavored vape can pass if the device itself is hard for kids to use. ### What exactly got cleared? The FDA granted marketing orders for four 5% nicotine pods made for the Glas G 2 device: Classic Menthol, Fresh Menthol, Gold, and Sapphire. Gold and Sapphire are the big news because they are the first fruit-flavored entries on the FDA’s authorized e-cigarette list, which now shows 45 legal products in total. The agency is careful on wording here — these products are authorized to be marketed, not declared safe. (fda.gov) ### Why is this different from past FDA decisions? Because the FDA spent years saying flavored vapes were especially risky for youth and denying huge numbers of applications built around fruit, candy, and dessert flavors. Even in March 2026, draft guidance still framed fruit flavors as a hard sell unless companies could really answer the youth-risk problem. This Glas decision doesn’t erase that older stance, but it does carve out a new exception with a very specific logic. (fda.gov) ### So what changed? Basically, the FDA bought the age-gating system. Glas’s device requires a user to verify age and identity with a government ID, pair the vape to a smartphone over Bluetooth, and keep the device near that phone to make it work. The app also runs random biometric check-ins, and the FDA said the company’s evidence showed adults could complete the process while youth and young adults could not. (fda.gov) ### Why does that matter so much? Because the FDA’s legal test is not “is this tobacco product harmless?” It’s whether letting it be sold is appropriate for public health overall — meaning adult smokers who might switch away from cigarettes have to count too. The agency said Glas showed a combination of adult benefit and youth protections strong enough to clear that bar. In plain English, the flavor was not the winning argument by itself — the lock on the product was. (fda.gov) ### Are health experts on board? Not cleanly. Some tobacco researchers see a real harm-reduction argument here — adults who won’t switch to tobacco-flavored vapes may switch to flavored ones instead. But others are worried the FDA just created a template that normalizes fruit flavors again, and several people in the field are also alarmed by signs that politics may have leaned on the process. That second fight — science versus political pressure — is now almost as important as the authorization itself. (fda.gov) ### Where does Trump fit in? The authorization came after reports that President Trump pressed FDA Commissioner Marty Makary to move the products through. STAT said Makary had been skeptical at first even though career staff supported the decision, and then changed course after Trump’s intervention was reported. That does not prove the science was wrong, but it does make the process look vulnerable in a part of the FDA that is supposed to be insulated from exactly this kind of pressure. (statnews.com) ### Does this mean fruit vapes are suddenly wide open? No — and that’s the catch. This is not a blanket green light for mango, berry, and candy vapes across the market. It is one company, one device system, four pods, and one specific youth-access argument the FDA says worked. But turns out that is still a major shift, because it shows other companies what kind of evidence might finally get flavored products through. (statnews.com) ### Bottom line The FDA did not decide fruit-flavored vapes are safe. It decided one locked-down fruit-flavored vape system might be worth the risk if it helps adult smokers leave cigarettes behind. That is a real policy turn — and now everyone will be fighting over whether it stays narrow or becomes the new rule. (fda.gov)